Table 2 Discontinuation and adverse events of prophylactic micafungin during first induction chemotherapy
From: Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy
| Â | Number of patients (%) |
|---|---|
Incidence of fungal infection | 3/65 (4.6) |
 Proven fungal infection | 1/65 (1.5) |
 Probable fungal infection | 0 |
 Possible fungal infection | 2/65 (3.1) |
Discontinuation of prophylactic micafungin | 19/65 (29.2) |
 Cause of discontinuation | |
  Suspected fungal infections | 3/65 (4.6) |
  Prolonged neutropenic fever | 14/65 (21.5) |
  Adverse events | 2/65 (3.1) |
Micafungin treatment completed | 46/65 (70.8) |
Switch to another antifungal agent | 18/65 (27.7) |
Adverse events related to micafungin | 3/65 (4.6) |
 Liver function test abnormality | 2/65 (3.1) |
  Grade 2 | 1/65 (1.5) |
  Grade 3 | 1/65 (1.5) |
 Allergic reaction | 1/65 (1.5) |
  Grade 2 | 1/65 (1.5) |
 No adverse event | 62/65 (95.4) |
Cause of mortality during induction chemotherapy | 3/65 (4.6) |
 Fungal infection (proven) | 1/65 (1.5) |
 Respiratory failure (pneumonia and pulmonary edema) | 1/65 (1.5) |
 Septic shock | 1/65 (1.5) |